Diagnostic Approach to Hair Loss with Elevated Eosinophils

Initial Risk Stratification

The American College of Physicians recommends that patients with mild eosinophilia (0.5-1.5 × 10⁹/L) be evaluated for allergic disorders or medications, as helminth infections account for 19-80% of cases in returning travelers 1
The National Comprehensive Cancer Network suggests that patients with moderate-to-severe eosinophilia (≥1.5 × 10⁹/L) require hematology referral if persisting >3 months after infectious causes are excluded 1
The National Comprehensive Cancer Network recommends that patients with hypereosinophilia (≥1.5 × 10⁹/L) undergo immediate evaluation for end-organ damage regardless of symptoms 2, 1

The National Comprehensive Cancer Network advises that patients with cardiac involvement, such as chest pain, dyspnea, heart failure symptoms, or arrhythmias, be evaluated for endomyocardial thrombosis/fibrosis, particularly with neoplastic HES variants 2, 1
The National Comprehensive Cancer Network recommends that patients with neurological symptoms, such as altered mental status, focal deficits, or peripheral neuropathy, be evaluated for CNS/spinal cord involvement 2, 1
The National Comprehensive Cancer Network suggests that patients with pulmonary involvement, such as persistent cough, wheezing, or infiltrates on imaging, be evaluated for eosinophilic pulmonary disease 2, 1

The National Comprehensive Cancer Network recommends that all patients with eosinophilia undergo a systematic diagnostic workup to exclude secondary causes, including allergic disorders, parasitic infections, and medication reactions 2
The American Academy of Dermatology suggests that patients with alopecia areata and concurrent eosinophilia have a higher risk of severe hair loss and nail abnormalities 2
The Centers for Disease Control and Prevention recommend that patients with a history of travel to endemic areas undergo testing for parasitic infections, including strongyloides and schistosomiasis 1

The National Comprehensive Cancer Network recommends that patients with confirmed hypereosinophilic syndrome and hair loss receive immediate corticosteroid therapy, with oral prednisone 1 mg/kg/day initially 1
The World Health Organization suggests that patients with parasitic infections receive empiric treatment while awaiting results, including ivermectin for strongyloides and albendazole for ascariasis and hookworm 1
The National Comprehensive Cancer Network recommends that patients with myeloproliferative variants receive imatinib 100-400 mg daily for FIP1L1-PDGFRA-positive cases 2

The American College of Physicians recommends that patients with HES-related diffuse alopecia and massive perifollicular eosinophils receive long-term maintenance therapy and regular monitoring of AEC and organ function 1
The National Comprehensive Cancer Network suggests that patients with HES-related diffuse alopecia and massive perifollicular eosinophils have a high risk of relapse after treatment cessation and require regular monitoring 1